ClinicalTrials.gg
CompletedNCT05888103V-Mono ChinaUpdated Jan 13, 2026Results posted

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

A Phase 3 interventional study of Inclisiran and Matching Placebo for Inclisiran in Primary Hypercholesterolemia or Mixed Dyslipidemia, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.

Enrollment
12th of 16
207 · median 401
Started
2023
with 1 other
Phase 3
8 of 16
1 open now
Registered
9th of 16
by date
Lead sponsor
9 of 16
Novartis Pharmaceuticals

Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 3, and was the 9th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inclisiran in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein cholesterol (LDL-C) who were not on any lipid lowering therapy.

Read the detailed description

This study was designed as a randomized, double-blind, multi-center Phase III trial, with a placebo-controlled treatment period and an open label treatment period, to evaluate the efficacy and safety of inclisiran sodium 300 mg s.c. in participants aged 18 to 75 years with a low or moderate ASCVD risk and fasting LDL-C value of ≥ 130 mg/dL but \< 190 mg/dL who were not on any lipid lowering therapy.

The study consisted of 3 parts:

  • Screening: the screening period was up to 14 days to allow adequate time for the eligibility evaluations.
  • Core Part: a double-blind, placebo-controlled treatment period of 180 days in which eligible participants were randomized 1:1 to receive either inclisiran sodium 300 mg s.c.

(inclisiran group) or matching placebo s.c. (control group) on Day 1 and Day 90. The end of core part (EOC) visit was conducted on Day 180. The database lock for the core part was planned to occur after all randomized participants have completed the EOC visit (or have discontinued from the study before EOC). The primary analysis was conducted after the database lock for the core part.

  • Extension Part: an extended treatment period of 180 days. In the extension part, participants originally randomized to inclisiran in the core part were to continue the inclisiran treatment while participants initially randomized to placebo were to transit to the inclisiran. The extension part was to start from the Day 180 treatment dose (placebo in the inclisiran group and inclisiran for participants originally randomized to the control group).
03

Conditions studied

  • Primary Hypercholesterolemia or Mixed Dyslipidemia

Keywords

  • Inclisiran
  • LDL-C
  • monotherapy
  • atherosclerotic cardiovascular disease
  • atheroma
  • Atherosclerosis
  • lipid
  • lipid lowering therapy (LLT)
  • cholesterol
  • hypercholesteremia
  • mixed dyslipidemia
  • TC (total cholesterol)
  • Apo B
  • non HDL-C
  • Lp(a)
  • PCSK9
  • PCSK9 inhibitor
  • siRNA
  • low ASCVD risk
  • moderate ASCVD risk
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.
  • Fasting LDL-C of ≥ 130 mg/dL but \< 190 mg/dL
  • Triglycerides ≤ 400 mg/dL
  • Categorized as low or moderate ASCVD risk by the 2016 Chinese Guideline

Exclusion criteria

Exclusion Criteria:

  • Use of any LLT within 90 days prior to screening visit
  • History of ASCVD
  • Diabetes mellitus or fasting plasma glucose of ≥ 7.0 mmol/L or ≥ 6.5%
  • Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Inclisiran - Inclisiran

    Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c administered on Day 1, Day 90, and Day 270, and placebo on Day 180

    Drug: Inclisiran · Drug: Matching Placebo for Inclisiran

  • Placebo comparator
    Placebo- Inclisiran

    Placebo on Day 1 and Day 90 and Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) s.c on Day 180 and 270

    Drug: Inclisiran · Drug: Matching Placebo for Inclisiran

Interventions

  • Inclisiran s.c

    Also known as: KJX839

  • DrugMatching Placebo for Inclisiran

    Matching s.c. placebo

    Also known as: Placebo s.c.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

    Time frame: Baseline, Day 150

Secondary outcomes

  1. Absolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

    Time frame: Baseline, Day 150

  2. Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part

    Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein. The percentage change from baseline in PCSK9 at Day 150 was assessed.

    Time frame: Baseline, Day 150

  3. Absolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part

    Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein.

    Time frame: Baseline, Day 150

  4. Percentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.

    Time frame: Baseline, Day 150

  5. Absolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.

    Time frame: Baseline, Day 150

  6. Percentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.

    Time frame: Baseline, Day 150

  7. Absolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.

    Time frame: Baseline, Day 150

  8. Percentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.

    Time frame: Baseline, Day 150

  9. Absolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.

    Time frame: Baseline, Day 150

  10. Percentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.

    Time frame: Baseline, Day 150

  11. Absolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.

    Time frame: Baseline, Day 150

  12. Percentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).

    Time frame: Baseline, Day 150

  13. Absolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).

    Time frame: Baseline, Day 150

  14. Percentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part

    Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.

    Time frame: Baseline, Day 150

  15. Absolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part

    Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.

    Time frame: Baseline, Day 150

  16. Percentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.

    Time frame: Baseline, Day 150

  17. Absolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

    Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.

    Time frame: Baseline, Day 150

  18. Percentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part

    Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

    Time frame: Baseline, Day 330

  19. Absolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part

    Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

    Time frame: Baseline, Day 330

  20. Number of Participants With Adverse Events (AEs) During Core Part

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

    Time frame: Core part, from treatment start (Day 1) to Day 150

  21. Number of Participants With Adverse Events (AEs) During Extension Part

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

    Time frame: Extension part, from Day 181, up to Day 360

  22. Number of Participants With Adverse Events (AEs) - Cumulative Data (Core + Extension Part)

    An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

    Time frame: AEs are reported from first dose of study treatment until end of study treatment plus 30 days after the last study visit (or 90 days after the last administration of study drug, whichever is longer) up to a maximum timeframe of approximately 360 days

07

Results

Posted Apr 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneInclisiran - InclisiranPlacebo- Inclisiran
Started103104
Completed extension part study98101
Completed100101
Not completed33
Withdrew: Participant decision33

Outcome measures

PrimaryPercentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in LDL-C
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in LDL-CInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-45.87 (-49.33 to -42.42)1.62 (-1.77 to 5.02)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -47.50 · 95% CI -52.35 to -42.65
SecondaryAbsolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in LDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-69.05 (-73.95 to -64.15)0.68 (-4.13 to 5.49)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -69.73 · 95% CI -76.60 to -62.86
SecondaryPercentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part

Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein. The percentage change from baseline in PCSK9 at Day 150 was assessed.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in PCSK9
Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part
% change in PCSK9Inclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part-71.95 (-77.68 to -66.22)5.88 (0.24 to 11.52)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -77.83 · 95% CI -85.86 to -69.80
SecondaryAbsolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part

Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA) that causes degradation of protein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA (mRNA) leading to the reduction of PCSK9 protein.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · ng/mL
Absolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part
ng/mLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in PCSK9 (ng/mL) From Baseline at Day 150 - Core Analysis: Core Part-217.14 (-230.15 to -204.13)9.47 (-3.24 to 22.17)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -226.61 · 95% CI -244.77 to -208.45
SecondaryPercentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in total cholesterol
Percentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in total cholesterolInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-29.88 (-32.32 to -27.43)1.61 (-0.78 to 4.01)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -31.49 · 95% CI -34.91 to -28.07
SecondaryAbsolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Total cholesterol is a measure of all the cholesterol in the blood. It includes low-density lipoprotein (LDL), high-density lipoprotein (HDL) and a portion of triglycerides.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in Total Cholesterol (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-68.82 (-74.37 to -63.28)2.64 (-2.80 to 8.09)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -71.46 · 95% CI -79.24 to -63.69
SecondaryPercentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in HDL-C
Percentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in HDL-CInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in High-density Lipoprotein Cholesterol (HDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part12.24 (7.62 to 16.86)9.30 (4.74 to 13.86)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.3743 · Ls mean difference: 2.94 · 95% CI -3.55 to 9.42
SecondaryAbsolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

HDL-C stands for high-density lipoprotein cholesterol, often referred to as the "good" cholesterol. This is because HDL cholesterol helps remove other forms of cholesterol from the bloodstream. It picks up excess cholesterol in the blood and carries it back to the liver, where it is broken down and flushed out of the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part4.66 (2.80 to 6.52)3.60 (1.76 to 5.43)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.4228 · Ls mean difference: 1.07 · 95% CI -1.54 to 3.68
SecondaryPercentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in non-HDL-C
Percentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in non-HDL-CInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-40.71 (-43.57 to -37.85)-0.14 (-2.93 to 2.66)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -40.57 · 95% CI -44.57 to -36.57
SecondaryAbsolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Non-HDL cholesterol is a measure of all the "bad" types of cholesterol in the blood, excluding HDL cholesterol. It is calculated by subtracting HDL cholesterol from total cholesterol. Non-HDL cholesterol includes all the types of cholesterol other than HDL cholesterol, and higher levels of non-HDL cholesterol can increase the risk of cardiovascular disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in Non-HDL-C (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-73.48 (-78.63 to -68.33)-1.14 (-6.19 to 3.91)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -72.34 · 95% CI -79.56 to -65.13
SecondaryPercentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in apolipoprotein B
Percentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in apolipoprotein BInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Apolipoprotein B (ApoB) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-36.63 (-39.40 to -33.86)0.21 (-2.50 to 2.93)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -36.84 · 95% CI -40.72 to -32.96
SecondaryAbsolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Apolipoprotein B (ApoB) is a protein that helps carry fat and cholesterol through the body. It is encoded by the APOB gene. ApoB attaches to negative types of cholesterol that cause plaque buildup in blood vessels, which can lead to damage and heart disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in ApoB (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-42.64 (-45.78 to -39.49)-0.76 (-3.85 to 2.32)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -41.87 · 95% CI -46.28 to -37.47
SecondaryPercentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in apolipoprotein A-1
Percentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in apolipoprotein A-1Inclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Apolipoprotein A-1 (ApoA-1) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part5.11 (2.34 to 7.88)3.06 (0.33 to 5.79)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.3011 · Ls mean difference: 2.05 · 95% CI -1.84 to 5.93
SecondaryAbsolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Apolipoprotein A1 (ApoA1) is the primary protein associated with high-density lipoprotein (HDL) particles, and plays a central role in reverse cholesterol transport. HDL cholesterol (HDL-C) and ApoA1 concentrations are inversely related to the risk for coronary artery disease (CAD).

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in ApoA-1 (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part6.44 (2.72 to 10.16)3.31 (-0.35 to 6.98)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.2403 · Ls mean difference: 3.13 · 95% CI -2.09 to 8.35
SecondaryPercentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part

Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in lipoprotein (a)
Percentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part
% change in lipoprotein (a)Inclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Lipoprotein (a) (Lp(a)) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part-23.84 (-31.20 to -16.48)6.43 (-0.77 to 13.62)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: -30.27 · 95% CI -40.58 to -19.95
SecondaryAbsolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part

Often referred to as Lp(a), lipoprotein (a) is a type of lipoprotein that is genetically inherited and in high levels is a common independent risk factor for heart disease.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · nmol/L
Absolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part
nmol/LInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in Log-transformed Lp(a) (Nmol/L) From Baseline at Day 150 - Core Analysis: Core Part0.68 (0.63 to 0.74)1.01 (0.93 to 1.09)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = <0.0001 · Ls mean difference: 0.68 · 95% CI 0.60 to 0.76
SecondaryPercentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · % change in Triglyceride
Percentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
% change in TriglycerideInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part3.49 (-4.44 to 11.43)0.48 (-7.01 to 7.97)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.5877 · Ls mean difference: 3.01 · 95% CI -7.88 to 13.91
SecondaryAbsolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part

Triglycerides are fats from the food we eat. Most of the fats we eat (like butter) are in triglyceride form. Extra calories, alcohol and sugar in the body turn into triglycerides. The body stores them in fat cells throughout the body.

Time frame:
Baseline, Day 150
Reported as:
Least squares mean · mg/dL
Absolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in Triglyceride (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part-15.32 (-31.86 to 1.22)-7.36 (-23.67 to 8.94)
Statistical analysis
  • Inclisiran - Inclisiran vs Placebo- Inclisiran · ANCOVA · p = 0.5019 · Ls mean difference: -7.96 · 95% CI -31.17 to 15.26
SecondaryPercentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part

Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · % change in LDL-C
Percentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part
% change in LDL-CInclisiran - InclisiranPlacebo- Inclisiran
Percentage Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part-45.45 (-48.57 to -42.34)—
SecondaryAbsolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part

Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats through the bloodstream. Because of their structure, fats can't move through the blood on their own. So, lipoproteins carry fats to various cells in the body.

Time frame:
Baseline, Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part
mg/dLInclisiran - InclisiranPlacebo- Inclisiran
Absolute Change in LDL-C (mg/dL) From Baseline at Day 330 - Final Analysis: Core Part + Extension Part-67.55 (-72.39 to -62.72)—
SecondaryNumber of Participants With Adverse Events (AEs) During Core Part

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

Time frame:
Core part, from treatment start (Day 1) to Day 150
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) During Core Part
ParticipantsInclisiran - InclisiranPlacebo- Inclisiran
Adverse events (AEs)7370
-Adverse events Treatment-related144
Serious adverse events (SAEs)53
-SAEs Treatment-related00
Fatal SAEs00
-Fatal SAEs Treatment-related00
AEs leading to treatment discontinuation00
-Treatment-related00
AEs requiring additional therapy5250
SecondaryNumber of Participants With Adverse Events (AEs) During Extension Part

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

Time frame:
Extension part, from Day 181, up to Day 360
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) During Extension Part
ParticipantsInclisiran - InclisiranPlacebo- Inclisiran
Adverse events (AEs)5247
-Adverse events Treatment-related915
Serious adverse events (SAEs)12
-SAEs Treatment-related00
Fatal SAEs00
-Fatal SAEs Treatment-related00
AEs leading to treatment discontinuation00
-Treatment-related00
AEs requiring additional therapy3628
SecondaryNumber of Participants With Adverse Events (AEs) - Cumulative Data (Core + Extension Part)

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject

Time frame:
AEs are reported from first dose of study treatment until end of study treatment plus 30 days after the last study visit (or 90 days after the last administration of study drug, whichever is longer) up to a maximum timeframe of approximately 360 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) - Cumulative Data (Core + Extension Part)
ParticipantsInclisiran - InclisiranPlacebo- Inclisiran
Adverse events8581
-Adverse events Treatment-related1818
SAEs65
-SAEs Treatment-related00
Fatal SAEs00
-Fatal SAEs Treatment-related00
AEs leading to treatment discontinuation00
-Treatment-related00
AEs requiring additional therapy6563

Adverse events

Collected over AEs are reported from first dose of study treatment until end of study treatment plus 30 days after the last study visit (or 90 days after the last administration of study drug, whichever is longer) up to a maximum timeframe of approximately 360 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran - Inclisiran: Core Part0/103 (0%)5/103 (4.9%)40/103 (38.8%)
Placebo - Inclisiran: Core Part0/104 (0%)3/104 (2.9%)27/104 (26%)
Inclisiran - Inclisiran: Extension Part0/100 (0%)1/100 (1%)25/100 (25%)
Placebo - Inclisiran: Extension Part0/101 (0%)2/101 (2%)20/101 (19.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventInclisiran - Inclisiran: Core PartPlacebo - Inclisiran: Core PartInclisiran - Inclisiran: Extension PartPlacebo - Inclisiran: Extension Part
Inguinal herniaGastrointestinal disorders0/1030/1041/1000/101
VertigoEar and labyrinth disorders0/1030/1040/1001/101
AppendicitisInfections and infestations0/1030/1040/1001/101
Acute coronary syndromeCardiac disorders1/1030/1040/1000/101
Vertigo positionalEar and labyrinth disorders1/1030/1040/1000/101
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1030/1040/1000/101
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/1030/1040/1000/101
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1030/1040/1000/101
Cerebrovascular accidentNervous system disorders1/1030/1040/1000/101
Cervical radiculopathyNervous system disorders1/1030/1040/1000/101
Most frequent other events
Most frequent other events
EventInclisiran - Inclisiran: Core PartPlacebo - Inclisiran: Core PartInclisiran - Inclisiran: Extension PartPlacebo - Inclisiran: Extension Part
Upper respiratory tract infectionInfections and infestations25/10317/10414/1009/101
Blood glucose increasedInvestigations10/1037/1044/1003/101
Blood creatine phosphokinase increasedInvestigations7/1036/1046/1007/101
Alanine aminotransferase increasedInvestigations6/1033/1045/1004/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inclisiran - InclisiranPlacebo- InclisiranTotal
Mean48.0 ± 9.9747.7 ± 10.6347.9 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)Inclisiran - InclisiranPlacebo- InclisiranTotal
Female5863121
Male454186
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inclisiran - InclisiranPlacebo- InclisiranTotal
American Indian or Alaska Native000
Asian103104207
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

28 sites
  • Novartis Investigative Site
    Fuzhou, Fujian 350025, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Zhongshan, Guangdong 528403, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Changsha, Hunan 410003, China
  • Novartis Investigative Site
    Changsha, Hunan 410011, China
  • Novartis Investigative Site
    Hohhot, Inner Mongolia 010017, China
  • Novartis Investigative Site
    Changzhou, Jiangsu 213004, China
  • Novartis Investigative Site
    Xuzhou, Jiangsu 221003, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330009, China
  • Novartis Investigative Site
    Jinzhou, Liaoning 121001, China
  • Novartis Investigative Site
    Linyi, Shandong 276000, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030002, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin Municipality 300121, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310006, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Beijing, 101200, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200120, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Tianjin, 300140, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from eligible studies. these requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Apr 2024, 8 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 8 months is below that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2023
First posted
Jun 5, 2023
StartActual
Jul 11, 2023
Primary completionActual
Apr 2, 2024
CompletionActual
Oct 24, 2024
Results first posted
Apr 20, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05888103
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Jul 11, 2023
Primary completion
Apr 2, 2024
Completion
Oct 24, 2024
Results posted
Apr 20, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion